2cureX AB (2CUREX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 2cureX AB (2CUREX) has a cash flow conversion efficiency ratio of 3.288x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.06 Million ≈ $221.47K USD) by net assets (Skr626.00K ≈ $67.37K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 2cureX AB net asset quality index to measure how much of total assets are equity-financed.
2cureX AB - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how 2cureX AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does 2cureX AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
2cureX AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 2cureX AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Golden Sky Minerals Corp
V:AUEN
|
0.777x |
|
Bluelinea SA
PA:ALBLU
|
-0.615x |
|
Lakshmi Finance & Industrial Corporation Limited
NSE:LFIC
|
-0.054x |
|
Trajano Iberia Socimi SA
MC:YTRA
|
0.005x |
|
AquaBounty Technologies Inc
NASDAQ:AQB
|
0.480x |
|
Exact Therapeutics AS
OL:EXTX
|
-0.697x |
|
Pacte Novation
PA:MLPAC
|
N/A |
|
Kanger International Bhd
KLSE:0170
|
-0.041x |
Annual Cash Flow Conversion Efficiency for 2cureX AB (2015–2024)
The table below shows the annual cash flow conversion efficiency of 2cureX AB from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see 2cureX AB stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr5.10 Million ≈ $548.73K |
Skr-4.63 Million ≈ $-497.83K |
-0.907x | +64.90% |
| 2023-12-31 | Skr12.08 Million ≈ $1.30 Million |
Skr-31.22 Million ≈ $-3.36 Million |
-2.585x | -297.53% |
| 2022-12-31 | Skr43.03 Million ≈ $4.63 Million |
Skr-27.98 Million ≈ $-3.01 Million |
-0.650x | -162.37% |
| 2021-12-31 | Skr74.34 Million ≈ $8.00 Million |
Skr-18.43 Million ≈ $-1.98 Million |
-0.248x | -24.76% |
| 2020-12-31 | Skr58.86 Million ≈ $6.33 Million |
Skr-11.69 Million ≈ $-1.26 Million |
-0.199x | +29.07% |
| 2019-12-31 | Skr28.08 Million ≈ $3.02 Million |
Skr-7.86 Million ≈ $-846.29K |
-0.280x | -431.76% |
| 2018-12-31 | Skr13.62 Million ≈ $1.47 Million |
Skr1.15 Million ≈ $123.76K |
0.084x | +139.30% |
| 2017-12-31 | Skr20.24 Million ≈ $2.18 Million |
Skr-4.35 Million ≈ $-467.91K |
-0.215x | -240.95% |
| 2016-12-31 | Skr7.91 Million ≈ $851.78K |
Skr1.21 Million ≈ $129.84K |
0.152x | +160.87% |
| 2015-12-31 | Skr8.19 Million ≈ $881.25K |
Skr-2.05 Million ≈ $-220.70K |
-0.250x | -- |
About 2cureX AB
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.